Resumo

CASTRO-MOLLO, Melanie; RUIZ, Rossana; ROQUE, Katia  e  MAS, Luis. Challenges and advances in metastatic non-small cell lung cancer with EGFR mutation. Rev. Fac. Med. Hum. [online]. 2024, vol.24, n.2, pp.132-138.  Epub 29-Abr-2024. ISSN 1814-5469.  http://dx.doi.org/10.25176/rfmh.v24i2.6441.

Tyrosine kinase inhibitors have dramatically changed the clinical outcomes for patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations. However, there are still challenges in the management of patients with this mutation in a metastatic setting, such as intrinsic and acquired resistance to tyrosine kinase inhibitors. We will discuss the latest advances and new strategies in first-line treatment, osimertinib resistance, and exon 20 mutation treatment.

Palavras-chave : Epidermal growth factor receptor; Non-small cell Lung cancer; Tyrosine kinase inhibitors. (Source: MeSH)..

        · resumo em Espanhol     · texto em Espanhol | Inglês     · Inglês ( pdf ) | Espanhol ( pdf )